Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3820275 | 0.98 | POLB (0.33) | POLBHTTPIK3CGBTK | |
| SCHEMBL29637752 | 0.85 | DDR1 (0.40) | POLBHTTKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL3822769 | 0.83 | POLB (0.33) | POLBHTT | |
| Hydrochloric Acid SCHEMBL5008312 | 0.83 | DDR1 (0.39) | POLBHTT | |
| SCHEMBL3826604 | 0.80 | LMNA (0.36) | POLBHTTKDM4EALDH1A1 | |
| SCHEMBL3828653 | 0.78 | ELANE (0.43) | POLBHTTKDM4EALDH1A1 | |
| SCHEMBL5008313 | 0.76 | MEN1 (0.37) | POLBHTTCYP2C19KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL3829380 | 0.76 | ELANE (0.43) | POLBHTTKDM4EALDH1A1 | |
| SCHEMBL114334 | 0.75 | MAPT (0.44) | POLBHTTKDM4EALDH1A1 | |
| SCHEMBL3828276 | 0.75 | MEN1 (0.44) | POLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324863-A1 | 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2022-10-13 | — | — | US | disclosed |
| CN-110678468-B | 5, 6-fused bicyclic compounds and compositions thereof for the treatment of parasitic diseases | 诺华股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-11384078-B2 | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2022-07-12 | — | — | US | disclosed |
| EP-3630771-A1 | 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | Novartis AG (CH) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018220531-A1 | 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2018-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384078-B2 | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | IL5, CYP3A5, ABCB11 | POLB 4529/4885HTT 2088/4885PIK3CG 526/4885 |
| US-20220324863-A1 | 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IL5, CYP3A5, ABCB11 | POLB 4529/4885HTT 2131/4885PIK3CG 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.